ExcelMale
Menu
Home
What's new
Latest activity
Forums
New posts
Search forums
What's new
New posts
Latest activity
Videos
Lab Tests
Doctor Finder
Buy Books
About Us
Men’s Health Coaching
Log in
Register
What's new
Search
Search
Search titles only
By:
New posts
Search forums
Menu
Log in
Register
Navigation
Install the app
Install
More options
Contact us
Close Menu
Forums
ExcelFemale
HRT in Women
A current perspective into young female sex hormone replacement
JavaScript is disabled. For a better experience, please enable JavaScript in your browser before proceeding.
You are using an out of date browser. It may not display this or other websites correctly.
You should upgrade or use an
alternative browser
.
Reply to thread
Message
<blockquote data-quote="madman" data-source="post: 186541" data-attributes="member: 13851"><p><strong>A current perspective into young female sex hormone replacement: <span style="color: rgb(184, 49, 47)">a review </span></strong></p><p><strong><span style="color: rgb(184, 49, 47)"></span></strong></p><p><strong><span style="color: rgb(184, 49, 47)"></span></strong></p><p><strong><span style="color: rgb(184, 49, 47)"></span></strong></p><p><strong><span style="color: rgb(184, 49, 47)">ABSTRACT</span></strong></p><p></p><p><span style="color: rgb(0, 0, 0)"><strong>Introduction:</strong></span> Hormone replacement in females with hypogonadism is advocated to address the various clinical aspects of estrogen deficiency.</p><p></p><p><strong>Areas covered:</strong> This article focuses on hormone replacement in young females with hypogonadism, including a rationale as to why hormone replacement in such patients differs from treatment in postmenopausal females, a summary of symptoms encountered by females with hypogonadism, and a comprehensive discussion of the various treatment options available, specifically focusing on the latest advances in the subject. A Medline search was conducted using different combinations of relevant keywords, giving preference to recent publications.</p><p></p><p><strong>Expert opinion: </strong><span style="color: rgb(184, 49, 47)"><em>Whilst traditionally oral contraceptive pills (containing ethynyl estradiol) were commonly used as a form of hormone replacement,</em></span><em><span style="color: rgb(184, 49, 47)"> it is now increasingly recognized that this is not the optimal treatment option. </span><span style="color: rgb(44, 130, 201)"><u>Physiological hormone replacement with transdermal estradiol is found to be superior</u>. Evidence suggests that micronized progesterone may be associated with fewer side effects, although its effect on endometrial protection is not yet proven.</span></em> Synthetic progestins confer varying degrees of androgenic and thromboembolic properties which should be kept in mind when prescribing individualized treatment. Further studies in different sub-cohorts of female patients with hypogonadism might help address the specific needs of individual patients.</p><p></p><p></p><p></p><p><strong>Article highlights </strong></p><p></p><p>● <span style="color: rgb(184, 49, 47)">The etiology of female hypogonadism is varied and may be classified as premature ovarian insufficiency (failure arising from the ovaries themselves) or secondary gonadal failure, also known as hypogonadotropic hypogonadism; the result of inadequate gonadotropin stimulation. </span></p><p></p><p>● <span style="color: rgb(184, 49, 47)">Women exhibiting features of gonadal failure prior to 50 years of age, especially prior to the age of 40, should be considered for sex hormone replacement therapy in order to avoid the complications of early menopause (menopausal symptoms, increased mortality mainly related to cardiovascular disease, bone health, and neurological sequelae). </span></p><p></p><p>● <span style="color: rgb(184, 49, 47)">By prescribing sex hormone replacement, one aims to restore normal physiological states, therefore in such a context the term ‘replacement’ is indeed pertinent as opposed to the concept of ‘extension’ of hormone therapy in the post-menopausal age group</span>.</p><p></p><p>● <span style="color: rgb(184, 49, 47)">The hormonal replacement consists of an estrogen component as well as a progestogen component, in females possessing a uterus. </span></p><p></p><p>● <span style="color: rgb(44, 130, 201)">Oestradiol is superior to ethinyloestradiol in terms of cardiovascular parameters, thromboembolic risk, and bone health. Furthermore, the use of transdermal or transvaginal estrogen therapy has been associated with a decreased risk of thromboembolism and possibly stroke, when compared to the classical oral formulation. </span></p><p></p><p>● <span style="color: rgb(184, 49, 47)">Different progestogens have a varying affinity to the progesterone receptor and other steroid receptors: mineralocorticoid, glucocorticoid, and androgen receptors. These differing actions, together with other factors including route of administration, pharmacokinetics, and protein-binding strength, explains the differing androgenic and thromboembolic profiles.</span></p><p></p><p>● <span style="color: rgb(44, 130, 201)">Treatment with testosterone was found to have positive effects on cardiometabolic risk factors, quality of life, and neurocognitive functions but long-term studies confirming safety and efficacy are lacking. </span></p><p></p><p>● <span style="color: rgb(184, 49, 47)">With regards to follow up, a multidisciplinary setting is advisable and aims to address specific patients’ needs according to the varied etiology of female hypogonadism.</span></p><p></p><p></p><p></p><p></p><p><strong>4. Symptoms of estrogen deficiency in young females </strong></p><p></p><p><em><span style="color: rgb(184, 49, 47)">Early menopause is associated with increased mortality [17– 22] mainly related to cardiovascular disease. They also have increased morbidity related to bone health and neurological sequelae [2,16]. </span></em></p><p></p><p><strong>4.1. <span style="color: rgb(184, 49, 47)">Cardiovascular consequences</span> </strong></p><p><strong>4.2. <span style="color: rgb(184, 49, 47)">Bone related consequences </span></strong></p><p><strong>4.3. <span style="color: rgb(184, 49, 47)">Cognitive function</span> </strong></p><p><strong>4.4. <span style="color: rgb(184, 49, 47)">Other symptoms</span> </strong></p><p><strong></strong></p><p><strong></strong></p><p><strong></strong></p><p><strong>5. Hormone replacement therapy <span style="color: rgb(184, 49, 47)">(HRT)</span> </strong></p><p></p><p><em><span style="color: rgb(184, 49, 47)">T<em>h</em>e hormonal replacement consists of an estrogen component as well as a progestogen component, in females possessing a uterus. Replacement aims to promote and maintain secondary sexual characteristics and, as already alluded to, to reduce the risk of developing long-term complications such as cardiovascular disease and osteoporosis [4]. Both estrogen and progestogen can be administered via multiple different formulations. Recently, the management of female patients with hypogonadism is moving away from the conventional oral contraceptive pill and post-menopausal hormone replacement therapy, toward a more physiological hormonal mode of replacement [2,6,45,55,56]. </span></em></p><p></p><p><strong>5.1. <span style="color: rgb(184, 49, 47)">Estrogen replacement</span></strong></p><p><strong>5.2. <span style="color: rgb(184, 49, 47)">Progestogen replacement</span></strong></p><p><strong></strong></p><p><strong>5.3. <span style="color: rgb(184, 49, 47)">Testosterone treatment</span> </strong></p><p><em><span style="color: rgb(44, 130, 201)">Around 50% of endogenous testosterone in females is produced by the ovaries [110]. Therefore conceptually, there is an element of androgen deficiency in patients with premature ovarian insufficiency which may play a role in some of the symptoms experienced by these patients [15].</span></em> <em><span style="color: rgb(184, 49, 47)">In postmenopausal females, testosterone treatment may be effective in improving sexual function [111]; however, long-term effects may not be clear [112]. In a randomized placebo-controlled trial in patients with bilateral salpingo-oophorectomy and hysterectomy, patients treated with 300ug of testosterone were found to have an improvement in the sexual activity score and treatment was well tolerated over a 24 week period [113]. Androgen replacement, in patients with Turner’s syndrome having POI, was found to be safe and provided beneficial effects on body composition, neurocognition, and quality of life [114]. Treatment with androgens in patients with POI should be considered only after obtaining comprehensive-informed consent, which includes information about the emerging evidence regarding androgen treatment and its beneficial outcomes, but also information about the paucity of data regarding long-term health effects [6].</span></em></p><p></p><p></p><p></p><p></p><p><strong>7. Conclusion </strong></p><p></p><p><em><strong><span style="color: rgb(184, 49, 47)">In premenopausal females, hormonal replacement of ovarian sex steroids is truly replacing hormones that would normally be present in this age group. It is in fact paramount to prevent the morbidity and mortality associated without treatment.</span></strong></em> <span style="color: rgb(44, 130, 201)"><em><strong>Recent advances and studies have shown that some of the more recently available drugs can better mimic normal ovarian physiology, in such a way to reduce menopausal symptoms, whilst maintaining bone health and cardiovascular protectivity. </strong></em></span><em><strong><span style="color: rgb(184, 49, 47)">In this review, we have highlighted the latest approaches to replacement whilst discussing the various options available. </span></strong></em></p></blockquote><p></p>
[QUOTE="madman, post: 186541, member: 13851"] [B]A current perspective into young female sex hormone replacement: [COLOR=rgb(184, 49, 47)]a review ABSTRACT[/COLOR][/B] [COLOR=rgb(0, 0, 0)][B]Introduction:[/B][/COLOR] Hormone replacement in females with hypogonadism is advocated to address the various clinical aspects of estrogen deficiency. [B]Areas covered:[/B] This article focuses on hormone replacement in young females with hypogonadism, including a rationale as to why hormone replacement in such patients differs from treatment in postmenopausal females, a summary of symptoms encountered by females with hypogonadism, and a comprehensive discussion of the various treatment options available, specifically focusing on the latest advances in the subject. A Medline search was conducted using different combinations of relevant keywords, giving preference to recent publications. [B]Expert opinion: [/B][COLOR=rgb(184, 49, 47)][I]Whilst traditionally oral contraceptive pills (containing ethynyl estradiol) were commonly used as a form of hormone replacement,[/I][/COLOR][I][COLOR=rgb(184, 49, 47)] it is now increasingly recognized that this is not the optimal treatment option. [/COLOR][COLOR=rgb(44, 130, 201)][U]Physiological hormone replacement with transdermal estradiol is found to be superior[/U]. Evidence suggests that micronized progesterone may be associated with fewer side effects, although its effect on endometrial protection is not yet proven.[/COLOR][/I] Synthetic progestins confer varying degrees of androgenic and thromboembolic properties which should be kept in mind when prescribing individualized treatment. Further studies in different sub-cohorts of female patients with hypogonadism might help address the specific needs of individual patients. [B]Article highlights [/B] ● [COLOR=rgb(184, 49, 47)]The etiology of female hypogonadism is varied and may be classified as premature ovarian insufficiency (failure arising from the ovaries themselves) or secondary gonadal failure, also known as hypogonadotropic hypogonadism; the result of inadequate gonadotropin stimulation. [/COLOR] ● [COLOR=rgb(184, 49, 47)]Women exhibiting features of gonadal failure prior to 50 years of age, especially prior to the age of 40, should be considered for sex hormone replacement therapy in order to avoid the complications of early menopause (menopausal symptoms, increased mortality mainly related to cardiovascular disease, bone health, and neurological sequelae). [/COLOR] ● [COLOR=rgb(184, 49, 47)]By prescribing sex hormone replacement, one aims to restore normal physiological states, therefore in such a context the term ‘replacement’ is indeed pertinent as opposed to the concept of ‘extension’ of hormone therapy in the post-menopausal age group[/COLOR]. ● [COLOR=rgb(184, 49, 47)]The hormonal replacement consists of an estrogen component as well as a progestogen component, in females possessing a uterus. [/COLOR] ● [COLOR=rgb(44, 130, 201)]Oestradiol is superior to ethinyloestradiol in terms of cardiovascular parameters, thromboembolic risk, and bone health. Furthermore, the use of transdermal or transvaginal estrogen therapy has been associated with a decreased risk of thromboembolism and possibly stroke, when compared to the classical oral formulation. [/COLOR] ● [COLOR=rgb(184, 49, 47)]Different progestogens have a varying affinity to the progesterone receptor and other steroid receptors: mineralocorticoid, glucocorticoid, and androgen receptors. These differing actions, together with other factors including route of administration, pharmacokinetics, and protein-binding strength, explains the differing androgenic and thromboembolic profiles.[/COLOR] ● [COLOR=rgb(44, 130, 201)]Treatment with testosterone was found to have positive effects on cardiometabolic risk factors, quality of life, and neurocognitive functions but long-term studies confirming safety and efficacy are lacking. [/COLOR] ● [COLOR=rgb(184, 49, 47)]With regards to follow up, a multidisciplinary setting is advisable and aims to address specific patients’ needs according to the varied etiology of female hypogonadism.[/COLOR] [B]4. Symptoms of estrogen deficiency in young females [/B] [I][COLOR=rgb(184, 49, 47)]Early menopause is associated with increased mortality [17– 22] mainly related to cardiovascular disease. They also have increased morbidity related to bone health and neurological sequelae [2,16]. [/COLOR][/I] [B]4.1. [COLOR=rgb(184, 49, 47)]Cardiovascular consequences[/COLOR] 4.2. [COLOR=rgb(184, 49, 47)]Bone related consequences [/COLOR] 4.3. [COLOR=rgb(184, 49, 47)]Cognitive function[/COLOR] 4.4. [COLOR=rgb(184, 49, 47)]Other symptoms[/COLOR] 5. Hormone replacement therapy [COLOR=rgb(184, 49, 47)](HRT)[/COLOR] [/B] [I][COLOR=rgb(184, 49, 47)]T[I]h[/I]e hormonal replacement consists of an estrogen component as well as a progestogen component, in females possessing a uterus. Replacement aims to promote and maintain secondary sexual characteristics and, as already alluded to, to reduce the risk of developing long-term complications such as cardiovascular disease and osteoporosis [4]. Both estrogen and progestogen can be administered via multiple different formulations. Recently, the management of female patients with hypogonadism is moving away from the conventional oral contraceptive pill and post-menopausal hormone replacement therapy, toward a more physiological hormonal mode of replacement [2,6,45,55,56]. [/COLOR][/I] [B]5.1. [COLOR=rgb(184, 49, 47)]Estrogen replacement[/COLOR] 5.2. [COLOR=rgb(184, 49, 47)]Progestogen replacement[/COLOR] 5.3. [COLOR=rgb(184, 49, 47)]Testosterone treatment[/COLOR] [/B] [I][COLOR=rgb(44, 130, 201)]Around 50% of endogenous testosterone in females is produced by the ovaries [110]. Therefore conceptually, there is an element of androgen deficiency in patients with premature ovarian insufficiency which may play a role in some of the symptoms experienced by these patients [15].[/COLOR][/I] [I][COLOR=rgb(184, 49, 47)]In postmenopausal females, testosterone treatment may be effective in improving sexual function [111]; however, long-term effects may not be clear [112]. In a randomized placebo-controlled trial in patients with bilateral salpingo-oophorectomy and hysterectomy, patients treated with 300ug of testosterone were found to have an improvement in the sexual activity score and treatment was well tolerated over a 24 week period [113]. Androgen replacement, in patients with Turner’s syndrome having POI, was found to be safe and provided beneficial effects on body composition, neurocognition, and quality of life [114]. Treatment with androgens in patients with POI should be considered only after obtaining comprehensive-informed consent, which includes information about the emerging evidence regarding androgen treatment and its beneficial outcomes, but also information about the paucity of data regarding long-term health effects [6].[/COLOR][/I] [B]7. Conclusion [/B] [I][B][COLOR=rgb(184, 49, 47)]In premenopausal females, hormonal replacement of ovarian sex steroids is truly replacing hormones that would normally be present in this age group. It is in fact paramount to prevent the morbidity and mortality associated without treatment.[/COLOR][/B][/I] [COLOR=rgb(44, 130, 201)][I][B]Recent advances and studies have shown that some of the more recently available drugs can better mimic normal ovarian physiology, in such a way to reduce menopausal symptoms, whilst maintaining bone health and cardiovascular protectivity. [/B][/I][/COLOR][I][B][COLOR=rgb(184, 49, 47)]In this review, we have highlighted the latest approaches to replacement whilst discussing the various options available. [/COLOR][/B][/I] [/QUOTE]
Insert quotes…
Verification
Post reply
Share this page
Facebook
Twitter
Reddit
Pinterest
Tumblr
WhatsApp
Email
Share
Link
Sponsors
Forums
ExcelFemale
HRT in Women
A current perspective into young female sex hormone replacement
This site uses cookies to help personalise content, tailor your experience and to keep you logged in if you register.
By continuing to use this site, you are consenting to our use of cookies.
Accept
Learn more…
Top